The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant’s high rate of infection.

Pancreatic cancer is a rare, yet elusive and deadly cancer, with a five-year survival rate of about 10%. If the cancer has metastasized, that rate lowers to 3%. And treatment options are extremely limited.

Kent, UK-based point-of-care test developer Psyros Diagnostics on Thursday announced it is being acquired by Prolight Diagnostics, based in Lund, Sweden, for SEK 65 million ($7.1 million).

On January 19, Hangzhou Bioer Technology Co., Ltd. signed a strategic cooperation agreement with Dell.

Research from the School of Medicine suggests how a newly developed gene therapy can treat Dravet syndrome, a severe form of epilepsy, and potentially prolong survival for people with the condition.

Ginkgo Bioworks said on Wednesday that it has acquired Project Beacon COVID-19, a Boston-based coronavirus testing organization.

Cancer diagnostics firm Oncocyte said Tuesday that it has entered into a collaboration and comarketing agreement with Thermo Fisher Scientific for two cancer in vitro diagnostic tests.

Molecular diagnostic company Canary Global announced on Tuesday that it received CE marking last week for its DigiGene COVID-19 Rapid Molecular Test Kit.

Today, the Top Employers Institute released the Top Employers China 2022 list of certified organizations. Danaher, Roche, Abbott, Ortho, Biomeier, BD and other companies have won the "Top Employers China 2022" certification.

Sema4 said Tuesday that it will acquire GeneDx from Opko Health for approximately $623 million in cash, stock consideration, and milestone payments.